Among all the bone-seeking radiopharmaceuticals, radium-223 is the first to confer an overall survival advantage in castration-resistant prostate cancer patients with bone metastases, according to experts from the University of Alabama in Birmingham. In a review article, they summarize the current research on radium-223, strontium-89, and similar agents designed localize to the site of bone metastases and deliver focal radiation.
RESULT: Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases
Cancer Letters (Pubmed) | Oct 28, 2012 (Free abstract. Full text $31.50)
Recent studies have shown that, contrary to previous thought, bone metastasic processes in prostate cancer involve osteoclastic as well as osteoblastic events, at least early on. These researchers from Detroit’s Karmanos Cancer Institute propose a two-drug combination that may act to prevent progression by metastasis to bone.
RESULT: Targeting Bone Remodeling by Isoflavone and 3,3′-Diindolylmethane in the Context of Prostate Cancer Bone Metastasis
PLoS One | Mar 7, 2012 (FREE FULL TEXT)